Blake Swearingen

Director, Clinical Development at T3D Therapeutics

Mr. Swearingen is clinical research and development professional with 30 years of experience in the pharmaceutical industry. He started his career as a medicinal chemist working with computational chemists and pharmacologists to design and synthesize anti-obesity and cardiovascular compounds. After leaving chemistry he spent 10+ years designing and conducting clinical trials for Zofran, Serevent, and other respiratory and CNS assets at Glaxo/Glaxo Welcome with management oversight of four CROs. For 15 years he was Senior Manager, then Project Director, of Global Project Management where he managed the development of assets in multiple therapeutic areas including CNS (migraine and restless leg syndrome). During that time, he collaborated with commercial and led the GSK R&D effort to sell a late-stage CNS asset. Mr. Swearingen later served as a consultant to AstraZeneca and built their market penetration plans for oncology products in eight countries. Most recently he was Senior Project Manager, Regulatory Advertising and Promotion at Indivior.


Previous companies

Parexel logo
Indivior logo


  • Director, Clinical Development

    Current role